About Accugenix
Accugenix is a company based in Newark (United States) founded in 1990 was acquired by Charles River Laboratories in August 2012. Accugenix offers products and services including Research Models and Services, Antibody Discovery Services, Integrated Drug Discovery, and Biologics Testing Solutions. Accugenix operates in a competitive market with competitors including BioAgilytix, Alderley Analytical, Tentamus, AFYREN and Nordic Bioscience, among others.
- Headquarter Newark, United States
- SectorsHealthcare
- Website accugenix.com
- Social LinkedIn X
- Acquired by Charles River Laboratories (Aug 2012)
- Investors
- Acquired byCharles River Laboratories
(Aug 2012)
Products & Services of Accugenix
Accugenix offers a comprehensive portfolio of products and services, including Research Models and Services, Antibody Discovery Services, Integrated Drug Discovery, and Biologics Testing Solutions.
Provides animal models and support for basic research in pharmaceuticals.
Offers comprehensive antibody development for therapeutic applications.
Manages target discovery to lead optimization for faster drug pipelines.
Conducts global testing for biologics from discovery to commercialization.
Investors in Accugenix
Accugenix has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Charles River Laboratories.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Provider of drug discovery and preclinical development services | 1947 | criver.com | Wilmington, United States |
Investor details for Accugenix
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Accugenix
2 dated milestones of Accugenix across 22 years, from founding to its latest funding, stage changes and deals.
- Founded Accugenix is founded.
- Exit Acquired by Charles River Laboratories.
Competitors of Accugenix
Accugenix operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as BioAgilytix, Alderley Analytical, Tentamus, AFYREN and Nordic Bioscience, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| bioagilytix.com | 2008 | Durham, United States | – | 446 | Large-molecule bioanalysis is provided for biologics and biosimilars development. | |
| alderleyanalytical.com | 2013 | Stockport, United Kingdom | $869,352 | 41 | Bioanalytical assays for drug development are developed and validated. | |
| tentamus.com | 2011 | Berlin, Germany | – | 368 | Analytical and quality assurance services are provided for diverse industries. | |
| afyren.com | 2012 | Paris, France | $25.59M | – | Analytical services are provided for microbiology, chemistry, and bioprocesses sectors. | |
| nordicbioscience.com | 1996 | Herlev, Denmark | – | 178 | Preclinical and clinical drug development CRO with proprietary in-house Biomarker platform | |
| solvias.com | 1999 | Kaiseraugst, Switzerland | – | – | Integrated R&D services are provided for pharmaceuticals and allied sectors. | |
| advion.com | 1993 | Ithaca, United States | $45.64M | 54 | Microfluidics and mass spectrometry products are provided for clinical research. | |
| synexagroup.com | 2003 | Cape Town, South Africa | – | – | Provider of comprehensive analytical and advisory services, specializing in biomarker services | |
| spore.bio | 2022 | Paris, France | $31.61M | – | Microbial detection technology is developed for life science industries. | |
| eag.com | 1978 | San Diego, United States | – | 601 | Company offering a suite of scientific services for materials, engineering, agri, and life science industries |
Detailed competitors of Accugenix
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Accugenix
The website of Accugenix (accugenix.com) receives about 11.9K visits a month.
- Monthly visits11.9K
▲ 323.3% vs previous month
Websites whose visitors overlap most with Accugenix. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| biosan.com | 100% | – | #4,452,450 | View details | |
medicitalia.it | medicitalia.it | 100% | – | #27,018 | – |
| mycometrics.com | 66% | 5.4K | #3,214,518 | View details | |
camlt.org | camlt.org | 62% | – | – | – |
ok-salute.it | ok-salute.it | 40% | – | #493,044 | – |
Similar companies to Accugenix
10 companies that operate in the same segment as Accugenix (Life Sciences Platforms & Tools), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Medidata is recognized as a leading provider of SaaS solutions for clinical research. | 1999 | New York, New York, United States | USD 41.5 M | – | – | |
AI-based solutions for health management are provided. | 2015 | Dallas, Texas, United States | USD 2.8 B | – | – | |
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.3 B | USD 301.49 M | 1,480 | |
Real-world health data is provided for research and decisions. | 2012 | Menlo Park, California, United States | USD 259.16 M | – | – | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M | – | – | |
Biological reagents and antibodies are developed for life science research. | 1998 | Cambridge, Cambridgeshire, United Kingdom | USD 78.8 M | – | – | |
Electron microscopy services and microanalysis instruments are provided. | 1956 | Waltham, Massachusetts, United States | – | USD 44.56 B | 125,000 | |
Novel therapeutics are discovered using an AI-enabled drug platform. | 2013 | New York, New York, United States | USD 456.66 M | USD 74.68 M | – | |
A platform for sharing and accessing academic research papers is provided. | 2008 | San Francisco, California, United States | USD 58.4 M | – | – | |
Developer of molecular diagnostic testing solutions | 1996 | Sunnyvale, California, United States | USD 19.1 M | USD 54.88 M | 208 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Accugenix
Accugenix was founded in 1990.
Accugenix is headquartered in Newark, United States. It is registered at Newark, New Jersey, United States.
Accugenix was founded in 1990 in Newark, United States, and acquired by Charles River Labs in 2012. Services in the microbiological testing sector focus on bacterial and fungal identification, strain typing, and environmental isolate analysis. DNA sequencing and MALDI-TOF technologies are employed, supported by proprietary libraries developed over two decades. Operations extend to more than 1,000 facilities worldwide, including genotypic identification, microbial detection, proteotypic analysis, and sequence-based methods.
Accugenix's top competitors include Alderley Analytical, BioAgilytix and AFYREN.
Accugenix offers Research Models and Services, Antibody Discovery Services, Integrated Drug Discovery, and Biologics Testing Solutions.
Accugenix has 1 investor. Key investors include Charles River Laboratories.
Yes. Accugenix was acquired by Charles River Laboratories in August 2012.